JP Morgan Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $12

JP Morgan analyst Anupam Rama has upgraded CytomX Therapeutics (NASDAQ: CTMX) from Neutral to Overweight and increased the price target from $7 to $12. This change reflects a positive outlook on the company's performance.